4523 Stock Overview
Eisai Co., Ltd. offers pharmaceutical products in Japan.
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥6,112.00|
|52 Week High||JP¥9,395.00|
|52 Week Low||JP¥5,011.00|
|1 Month Change||0.26%|
|3 Month Change||10.01%|
|1 Year Change||-33.04%|
|3 Year Change||13.31%|
|5 Year Change||8.10%|
|Change since IPO||275.30%|
Recent News & Updates
|4523||JP Pharmaceuticals||JP Market|
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned -0.1% over the past year.
|4523 Average Weekly Movement||3.9%|
|Pharmaceuticals Industry Average Movement||4.1%|
|Market Average Movement||3.9%|
|10% most volatile stocks in JP Market||8.1%|
|10% least volatile stocks in JP Market||2.1%|
Stable Share Price: 4523 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.
About the Company
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma.
Eisai Fundamentals Summary
|4523 fundamental statistics|
Is 4523 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4523 income statement (TTM)|
|Cost of Revenue||JP¥173.52b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 07, 2022
|Earnings per share (EPS)||114.19|
|Net Profit Margin||4.41%|
How did 4523 perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Does 4523 pay a reliable dividends?See 4523 dividend history and benchmarks
|Eisai dividend dates|
|Ex Dividend Date||Sep 29 2022|
|Dividend Pay Date||Nov 21 2022|
|Days until Ex dividend||51 days|
|Days until Dividend pay date||104 days|
Does 4523 pay a reliable dividends?See 4523 dividend history and benchmarks
Is 4523 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4523?
Other financial metrics that can be useful for relative valuation.
|What is 4523's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4523's PE Ratio compare to its peers?
|4523 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4151 Kyowa Kirin
4528 Ono Pharmaceutical
4578 Otsuka Holdings
Price-To-Earnings vs Peers: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the peer average (22.2x).
Price to Earnings Ratio vs Industry
How does 4523's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the JP Pharmaceuticals industry average (18.1x)
Price to Earnings Ratio vs Fair Ratio
What is 4523's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||53.5x|
|Fair PE Ratio||24.3x|
Price-To-Earnings vs Fair Ratio: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the estimated Fair Price-To-Earnings Ratio (24.3x).
Share Price vs Fair Value
What is the Fair Price of 4523 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4523 (¥6112) is trading above our estimate of fair value (¥5272.74)
Significantly Below Fair Value: 4523 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
How is Eisai forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4523's forecast earnings growth (8.8% per year) is above the savings rate (0.04%).
Earnings vs Market: 4523's earnings (8.8% per year) are forecast to grow faster than the JP market (8.7% per year).
High Growth Earnings: 4523's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4523's revenue (3.2% per year) is forecast to grow slower than the JP market (4.4% per year).
High Growth Revenue: 4523's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4523's Return on Equity is forecast to be low in 3 years time (8.3%).
Discover growth companies
How has Eisai performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4523 has a large one-off loss of ¥14.2B impacting its June 30 2022 financial results.
Growing Profit Margin: 4523's current net profit margins (4.4%) are lower than last year (8.8%).
Past Earnings Growth Analysis
Earnings Trend: 4523's earnings have grown by 6.9% per year over the past 5 years.
Accelerating Growth: 4523's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4523 had negative earnings growth (-45.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.2%).
Return on Equity
High ROE: 4523's Return on Equity (3.8%) is considered low.
Discover strong past performing companies
How is Eisai's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 4523's short term assets (¥620.9B) exceed its short term liabilities (¥301.9B).
Long Term Liabilities: 4523's short term assets (¥620.9B) exceed its long term liabilities (¥142.6B).
Debt to Equity History and Analysis
Debt Level: 4523 has more cash than its total debt.
Reducing Debt: 4523's debt to equity ratio has reduced from 37.8% to 11.5% over the past 5 years.
Debt Coverage: 4523's debt is well covered by operating cash flow (143.3%).
Interest Coverage: 4523 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Eisai current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4523's dividend (2.62%) is higher than the bottom 25% of dividend payers in the JP market (1.63%).
High Dividend: 4523's dividend (2.62%) is low compared to the top 25% of dividend payers in the JP market (3.62%).
Stability and Growth of Payments
Stable Dividend: 4523's dividends per share have been stable in the past 10 years.
Growing Dividend: 4523's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (140.1%), 4523's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (48.6%), 4523's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Haruo Naito (75 yo)
Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...
CEO Compensation Analysis
Compensation vs Market: Haruo's total compensation ($USD923.24K) is below average for companies of similar size in the JP market ($USD1.51M).
Compensation vs Earnings: Haruo's compensation has been consistent with company performance over the past year.
Experienced Management: 4523's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: 4523's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eisai Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Eisai Co., Ltd.
- Ticker: 4523
- Exchange: TSE
- Founded: 1941
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: JP¥1.752t
- Shares outstanding: 286.72m
- Website: https://www.eisai.co.jp
Number of Employees
- Eisai Co., Ltd.
- 4-6-10, Koishikawa
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/08 00:00|
|End of Day Share Price||2022/08/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.